by marcbacon | Dec 14, 2021
PsychoGenics Inc. announced the appointment of Stephen Morairty, Ph.D., as Vice President of Translational Neuroscience and Jean-Sebastien Valois, MSc, as Vice President of Engineering and AI Development. These key leadership roles support PsychoGenics as it grows its...
by marcbacon | Oct 11, 2021
PsychoGenics announces that Daniela Brunner Ph.D., Chief Innovation Officer, was named the recipient of Great Minds in STEMTM (GMiS) Scientist of the Year Award (GMiS 2021 Award Winners). Dr. Brunner was recognized for her contribution to the development of...
by marcbacon | Sep 25, 2020
Daniela Brunner, Chief Innovation Officer; Geoffrey Varty, Executive Vice President, Research Operations; and Leslie Street, Vice President, Medicinal Chemistry PsychoGenics Inc. announces the appointment of Daniela Brunner, Ph.D. as Chief Innovation Officer, Geoffrey...
by marcbacon | Sep 16, 2020
A phenotypic high-throughput approach to neuropsychiatric drug discovery Using its SmartCube platform along with machine learning algorithms, PsychoGenics has a powerful tool for the discovery of novel neuropsychiatric compounds. PsychoGenics has developed a...
by marcbacon | Jul 28, 2020
Multi-year drug discovery collaboration leveraging behavioral and physiological phenotypic screening and machine learning to identify novel neuropsychiatric drug candidates Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical...
